| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Hospital & Healthcare Services
|
Compare with Industry peers |
| Website | http://www.vijayadiagnostic.com | |
| Market Cap | 3,951.18 Cr. | |
| Enterprise Value(EV) | 3,804.42 Cr. | 2021-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 8.33 | Trailing Twelve Months Ending 2021-03 |
| Price-Earning Ratio (PE) | 47.04 | Trailing Twelve Months Ending 2021-03 |
| Industry PE | 40.42 | Trailing Twelve Months Ending 2021-03 |
| Book Value / Share | 43.72 | Trailing Twelve Months Ending 2021-03 |
| Price to Book Value | 8.96 | Calculated using Price: 391.70 |
| Dividend Yield | 0.00 | Period Ending 2021-03 |
| No. of Shares Subscribed | 10.20 Cr. | 101,965,926 Shares |
| FaceValue | 1 | |
| Company Profile | ||
|
The company is the largest integrated diagnostic chain in southern India, by operating revenue, and also one of the fastest-growing diagnostic chain by revenue for fiscal year 2020. It offer a one-stop solution for pathology and radiology testing services to its customers through its extensive operational network, which consists of 81 diagnostic centres and 11 reference laboratories across 13 cities and towns in the states of Telangana and Andhra Pradesh and in the National Capital Region and Kolkata as on June 30, 2021. The company offers a comprehensive range of approximately 740 routine and 870 specialized pathology tests and approximately 220 basic and 320 advanced radiology tests that cover a range of specialties and disciplines, as of June 30, 2021. Its test menu includes pathology tests ranging from basic biochemistry and clinical pathology to cytogenetics and high-end molecular diagnostic tests, and radiology tests ranging from basic echocardiograms, X-rays and ultrasounds to advanced radiology tests including computerised tomography (CT) scans, magnetic resonance imaging (MRI) scans, single photon emission computed tomography (SPECT) and advanced positron emission tomography CT (PET CT). It also offer a broad spectrum of health and wellness packages to its customers as per their requirements. The company focus on a customer centric approach to enhance the overall quality of its services for optimal customer satisfaction. For convenience of its customers, it provide value-added services such as home collection of specimens, house calls and various delivery or access modes (i.e., at diagnostic centres, SMS, email and web portal) for test reports. Several factors, including the strength of its brand, integrated services model, quality of its diagnostic services, center infrastructure and customer experience, convenience of its operational network and home collection in its core geographies are important differentiating factors in customers choosing it as their preferred diagnostic service provider, which helps it in retaining its customers, and sets it apart from its competitors. Business area of the company The company is one of the fastest-growing diagnostic chains in Southern India. It offers a one-stop solution for pathology and radiology testing services. Awards, accreditations and recognitions
Major events and milestones
|
||
Company Profile
The company is the largest integrated diagnostic chain in southern India, by operating revenue, and also one of the fastest-growing diagnostic chain by revenue for fiscal year 2020. It offer a one-stop solution for pathology and radiology testing services to its customers through its extensive operational network, which consists of 81 diagnostic centres and 11 reference laboratories across 13 cities and towns in the states of Telangana and Andhra Pradesh and in the National Capital Region and Kolkata as on June 30, 2021.
The company offers a comprehensive range of approximately 740 routine and 870 specialized pathology tests and approximately 220 basic and 320 advanced radiology tests that cover a range of specialties and disciplines, as of June 30, 2021. Its test menu includes pathology tests ranging from basic biochemistry and clinical pathology to cytogenetics and high-end molecular diagnostic tests, and radiology tests ranging from basic echocardiograms, X-rays and ultrasounds to advanced radiology tests including computerised tomography (CT) scans, magnetic resonance imaging (MRI) scans, single photon emission computed tomography (SPECT) and advanced positron emission tomography CT (PET CT).
It also offer a broad spectrum of health and wellness packages to its customers as per their requirements. The company focus on a customer centric approach to enhance the overall quality of its services for optimal customer satisfaction. For convenience of its customers, it provide value-added services such as home collection of specimens, house calls and various delivery or access modes (i.e., at diagnostic centres, SMS, email and web portal) for test reports. Several factors, including the strength of its brand, integrated services model, quality of its diagnostic services, center infrastructure and customer experience, convenience of its operational network and home collection in its core geographies are important differentiating factors in customers choosing it as their preferred diagnostic service provider, which helps it in retaining its customers, and sets it apart from its competitors.
Business area of the company
The company is one of the fastest-growing diagnostic chains in Southern India. It offers a one-stop solution for pathology and radiology testing services.
Awards, accreditations and recognitions
Major events and milestones
| 1 Day |
|
-0.28% |
| 1 Week |
|
-16.97% |
| 1 Month |
|
-10.46% |
| 3 Month |
|
+3.79% |
| 6 Month |
|
-30.97% |
| 1 Year |
|
|
| 2 Year |
|
|
| 5 Year |
|
|
| 10 Year |
|
| 3 years | 2019-03 | 2020-03 | 2021-03 | |
| Return on Equity (%) | 22.58 | 26.07 | 26.80 | |
| Return on Capital Employed (%) | 31.56 | 35.47 | 37.97 | |
| Return on Assets (%) | 11.42 | 14.11 | 16.72 |
| Particulars | 4 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2021-09* Rs. Cr. |
| Shh. Funds | 207 | 275 | 359 | 420 | |
| Non Curr. Liab. | 141 | 148 | 132 | 154 | |
| Curr. Liab. | 57 | 59 | 44 | 65 | |
| Minority Int. | 0 | 0 | 0 | 1 | |
| Equity & Liab. | 405 | 481 | 535 | 640 | |
| Non Curr. Assets | 268 | 294 | 296 | 388 | |
| Curr. Assets | 137 | 186 | 239 | 252 | |
| Misc. Exp. not W/O | |||||
| Total Assets | 405 | 481 | 535 | 640 |
| Particulars | 3 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Net Sales | 293 | 339 | 377 | |
| Other Income | 10 | 15 | 12 | |
| Total Income | 303 | 354 | 389 | |
| Total Expenditure | -184 | -206 | -211 | |
| PBIDT | 118 | 148 | 178 | |
| Interest | -14 | -15 | -15 | |
| Depreciation | -40 | -49 | -50 | |
| Taxation | -19 | -21 | -27 | |
| Exceptional Items | ||||
| PAT | 46 | 63 | 85 | |
| Minority Interest | ||||
| Share Associate | ||||
| Other Related Items | ||||
| Consolidated Net Profit | 46 | 63 | 85 | |
| Adjusted EPS | 102 | 138 | 19 |
| Particulars | 3 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Cash Fr. Operatn. | 91 | 106 | 130 | |
| Cash Fr. Inv. | -90 | -31 | -130 | |
| Cash Fr. Finan. | -7 | -30 | -49 | |
| Net Change | -7 | 46 | -49 | |
| Cash & Cash Eqvt | 10 | 56 | 7 |
|
Fri, 20 May 2022
Compliances-Reg.24(A)-Annual Secretarial Compliance we hereby submit the Annual Secretarial Compliance Report of the Company issued by Mr. Balaramakrishna Desina Practicing Company Secretary for the year ended March 31 2022. |
|
Fri, 20 May 2022
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that the Company is hosting Earnings Conference call for analysts and investors on Friday May 27 2022 at 2.00 PM IST to discuss on audited financial results of the Company for the quarter and year ended March 31 2022. The dial-in details of the call are enclosed.Please take the information on record. |
|
Tue, 17 May 2022
Board Meeting Intimation for Approval Of Audited Financial Results For The FY Ended March 31 2022 And Dividend. Vijaya Diagnostic Centre Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2022 inter alia to consider and approve Pursuant to Regulation 29 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 if any we hereby inform you that the meeting of the Board of Directors of the Company is scheduled to be held on Thursday May 26 2022 inter-alia to consider and approve the following;1. Audited Standalone and Consolidated Financial Statements of the Company for the financial year ended March 31 2022 and 2. Recommend the final dividend if any for the financial year ended on March 31 2022.Kindly take the information on record. |
| Tue, 24 May 2022 |
Close Crossing Last Week Low
|
Making Lower Lows for 3 days
|
Close Within 52 Week Low Zone
|
High Decrease 1 Month
|
High Decrease 6 Months
|
Equities
M.F.
Sectors